药物涂层球囊与药物洗脱支架治疗新发冠状动脉病变:随机试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入7项随机对照试验共7138例患者,比较药物涂层球囊(DCB)与药物洗脱支架(DES)治疗新发冠状动脉病变。12个月时器械导向复合终点(心源性死亡、靶血管心肌梗死和靶病变血运重建)两组无差异(RR 1.02,95%CI 0.63-1.64;p=0.93;I²=52%),次级终点亦相当。结论认为DCB短期安全性和有效性不劣于现代DES,但需长期随访确认。
要点
- 12个月器械导向复合终点DCB与DES无显著差异(RR 1.02,95%CI 0.63-1.64)。
- 心源性死亡、靶血管心肌梗死、靶病变血运重建等次级终点两组相当。
- 使用西罗莫司涂层球囊的试验结果相似,敏感性分析支持主要发现稳定。
核心结论
- 对于新发冠状动脉病变,DCB血管成形术在短期安全性和有效性方面与现代DES相当。
- 需要长期随访以确认避免永久植入物是否能转化为临床获益。
研究设计与样本
- 系统综述与荟萃分析,纳入比较DCB与DES治疗成人新发冠状动脉病变的随机对照试验,要求报告≥9个月的临床结局。
- 排除仅涉及支架内再狭窄、分叉PCI或观察性设计的研究。
- 共纳入7项试验,7138例患者(DCB 3570例;DES 3568例)。
- 采用随机效应模型(DerSimonian-Laird法结合Hartung-Knapp调整)合并风险比(RR)及95%置信区间(CI)。
主要发现
- 12个月时器械导向复合终点(心源性死亡、靶血管心肌梗死和靶病变血运重建)两组无差异(RR 1.02,95%CI 0.63-1.64;p=0.93;I²=52%)。
- 心源性死亡(RR 1.26,95%CI 0.75-2.14)、靶血管心肌梗死(RR 0.71,95%CI 0.36-1.39)、靶病变血运重建(RR 1.09,95%CI 0.52-2.30)和靶血管血运重建(RR 0.98,95%CI 0.58-1.65)两组相当。
- 敏感性分析支持主要发现的稳定性,使用西罗莫司涂层球囊的试验结果相似。
关键数值与推荐
- 12个月器械导向复合终点:RR 1.02,95%CI 0.63-1.64;p=0.93;I²=52%。
- 心源性死亡:RR 1.26,95%CI 0.75-2.14。
- 靶血管心肌梗死:RR 0.71,95%CI 0.36-1.39。
- 靶病变血运重建:RR 1.09,95%CI 0.52-2.30。
- 靶血管血运重建:RR 0.98,95%CI 0.58-1.65。
临床怎么用
- 对于新发冠状动脉病变,DCB可作为DES的替代选择,短期安全性和有效性相当。
- 临床决策需结合患者个体情况,并考虑长期随访的必要性。
局限性
- 长期随访数据有限,需进一步确认避免永久植入物的临床获益。
- 异质性中等(I²=52%),需谨慎解读结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-coated balloon (DCB) angioplasty has emerged as a potential stent-free strategy for percutaneous coronary intervention (PCI) in de novo coronary artery disease, but robust randomised evidence on safety and efficacy compared with drug-eluting stents (DES) remains limited. METHODS: We conducted a comprehensive systematic review and meta-analysis of randomised controlled trials comparing DCB angioplasty with DES for de novo coronary lesions in adult patients reporting clinical outcomes at ≥9 months. PubMed, Embase and Cochrane CENTRAL were searched from inception to October 2025 without language restriction; trial registries and reference lists were screened manually. Studies limited to in-stent restenosis, bifurcation PCI or observational designs were excluded. Data were extracted independently by two reviewers. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models (DerSimonian-Laird method with Hartung-Knapp adjustment). Heterogeneity was assessed with I² and τ² statistics and 95% prediction intervals were reported. Risk of bias was appraised with the Cochrane Risk of Bias 2 tool. RESULTS: Seven trials encompassing 7138 patients (DCB 3570; DES 3568) were included. At 12 months, the device-oriented composite endpoint (cardiac death, target vessel myocardial infarction and target lesion revascularisation) showed no difference between strategies (RR 1.02, 95% CI 0.63 to 1.64; p=0.93; I²=52%). Secondary outcomes were comparable: cardiac death (1.26, 0.75 to 2.14), target vessel MI (0.71, 0.36 to 1.39), target lesion revascularisation (1.09, 0.52 to 2.30) and target vessel revascularisation (0.98, 0.58 to 1.65). Sensitivity analysis supported the stability of the primary findings. Trials using sirolimus coated balloons demonstrated similar results. CONCLUSIONS: DCB angioplasty shows comparable short-term safety and efficacy to modern DES for de novo coronary disease. Long-term follow-up is necessary to confirm whether avoidance of permanent implants translates into clinical benefit. PROSPERO REGISTRATION NUMBER: CRD420251175063.
引用
- Mondragon D, Garin D, Cook S, et al. Drug-coated balloons versus drug-eluting stents for de novo coronary lesions: a systematic review and meta-analysis of randomised trials. Heart. 2026. PMID: 42476907. doi:10.1136/heartjnl-2026-328324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。